July 16, 2009
Onsolis approved for breakthrough cancer pain
Onsolis is expected to be made available by Meda Pharmaceuticals in the fourth quarter of 2009, only through a restricted distribution program called the FOCUS (Full Ongoing Commitment to User Safety) Program and requires prescriber, pharmacy, and patient enrollment. The FOCUS program was created in accordance with the FDA's requirements to help ensure that the benefits outweigh the risks of Onsolis. The program will facilitate appropriate use of Onsolis and provide healthcare practitioners, patients, and caregivers support through training and education.
For more information call (919) 582-9050 or visit www.bdsinternational.com.